{"success":true,"data":{"pressRelease":{"id":"135390","rtpr_id":"nACSKQ6BDa","ticker":"SPRY","exchange":"NASDAQ","all_tickers":["SPRY"],"title":"SPRY ALERT: Securities Fraud Class Action Launched Against ARS Pharmaceuticals, Inc. - October 5, 2026 Deadline","author":"ACCESSWIRE","published_at":"2026-09-03T14:20:01.053Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 3, 2026 / Levi & Korsinsky, LLP announces that a securities class\naction lawsuit has been filed on behalf of investors who purchased or\notherwise acquired ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) securities.\n\nIf you suffered a loss on your ARS Pharmaceuticals investment and would like\nto explore a potential recovery under the federal securities laws, Learn about\nARS Pharmaceuticals Class Action (https://pr.report/puhc) or contact Joseph E.\nLevi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak\nto our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against ARS\nPharmaceuticals, Inc. that seeks to recover losses of shareholders who were\nadversely affected by alleged securities fraud between March 9, 2026 and June\n24, 2026.\n\nCASE DETAILS: According to the complaint, defendants provided overwhelmingly\npositive statements to investors while, at the same time, disseminating\nmaterially false and misleading statements and/or concealing material adverse\nfacts concerning the expected timeline for the expanded insurance coverage for\nneffy through CVS Caremark.\n\nOn June 24, 2026, after the market closed, ARS published a press release\nannouncing that the Company did not receive expanded insurance coverage for\nneffy through CVS Caremark by the guided July 1, 2026 deadline, which meant\nthat ARS did not have expanded insurance coverage for neffy for the summer or\nback-to-school allergy seasons. ARS stated that CVS Caremark reserved its\ndecision on the expanded insurance coverage for neffy until January 2027.\n\nOn this news, investors and analysts reacted immediately to ARS's revelation.\nThe price of ARS's common stock declined from a closing market price of $10.54\nper share on June 24, 2026 to $8.02 per share on June 25, 2026, a decline of\nover 23.9% in the span of just a single day.\n\nWHAT'S NEXT? If you purchased ARS Pharmaceuticals stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/puhd). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/spry-alert-securities-fraud-class-action-launched-against-ars-ph-1216272)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSKQ6BDa","title":"SPRY ALERT: Securities Fraud Class Action Launched Against ARS Pharmaceuticals, Inc. - October 5, 2026 Deadline","author":"ACCESSWIRE","ticker":"SPRY","created":"2026-09-03T14:20:01.053Z","tickers":["SPRY"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 3, 2026 / Levi & Korsinsky, LLP announces that a securities class\naction lawsuit has been filed on behalf of investors who purchased or\notherwise acquired ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) securities.\n\nIf you suffered a loss on your ARS Pharmaceuticals investment and would like\nto explore a potential recovery under the federal securities laws, Learn about\nARS Pharmaceuticals Class Action (https://pr.report/puhc) or contact Joseph E.\nLevi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak\nto our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against ARS\nPharmaceuticals, Inc. that seeks to recover losses of shareholders who were\nadversely affected by alleged securities fraud between March 9, 2026 and June\n24, 2026.\n\nCASE DETAILS: According to the complaint, defendants provided overwhelmingly\npositive statements to investors while, at the same time, disseminating\nmaterially false and misleading statements and/or concealing material adverse\nfacts concerning the expected timeline for the expanded insurance coverage for\nneffy through CVS Caremark.\n\nOn June 24, 2026, after the market closed, ARS published a press release\nannouncing that the Company did not receive expanded insurance coverage for\nneffy through CVS Caremark by the guided July 1, 2026 deadline, which meant\nthat ARS did not have expanded insurance coverage for neffy for the summer or\nback-to-school allergy seasons. ARS stated that CVS Caremark reserved its\ndecision on the expanded insurance coverage for neffy until January 2027.\n\nOn this news, investors and analysts reacted immediately to ARS's revelation.\nThe price of ARS's common stock declined from a closing market price of $10.54\nper share on June 24, 2026 to $8.02 per share on June 25, 2026, a decline of\nover 23.9% in the span of just a single day.\n\nWHAT'S NEXT? If you purchased ARS Pharmaceuticals stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/puhd). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/spry-alert-securities-fraud-class-action-launched-against-ars-ph-1216272)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-03T14:20:01.090116625Z","server_sent_at_ms":1788445201090},"received_at":"2026-09-03T14:20:01.149Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/spry-alert-securities-fraud-class-action-launched-against-ars-ph-1216272"},"analysis":{"id":"124274","press_release_id":"135390","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Securities fraud class action alleges ARS concealed material adverse facts about neffy's CVS Caremark coverage timeline","SPRY fell over 23.9% in one day (June 24-25, 2026) after the company missed its guided July 1 coverage expansion","CVS Caremark deferred its expanded-coverage decision on neffy to January 2027, leaving neffy without expanded coverage for summer and back-to-school allergy seasons","Litigation overhang with October 5, 2026 lead plaintiff deadline; potential discovery into commercial/guidance practices"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky, LLP announced that a securities class action was filed against ARS Pharmaceuticals on behalf of investors who purchased SPRY securities between March 9, 2026 and June 24, 2026.\n\nThe complaint alleges ARS made misleading statements about the expected timeline for expanded CVS Caremark insurance coverage for neffy; ARS disclosed on June 24, 2026 that coverage was not received by the guided July 1 deadline and that CVS Caremark deferred its decision to January 2027.\n\nOn that disclosure, SPRY shares fell from $10.54 to $8.02 in a single day, a decline of over 23.9%.\n\nThe release itself is plaintiff-firm marketing with an October 5, 2026 lead plaintiff deadline rather than new issuer disclosure; the adverse coverage news was already public in June.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm class action solicitation -- suppress; the underlying CVS Caremark coverage delay was already disclosed and priced in during June 2026."},"keyFigures":{"customDimensions":{"class_period":"March 9, 2026 to June 24, 2026","stock_decline_pct":"23.9%","close_after_disclosure":8.02,"close_before_disclosure":10.54,"lead_plaintiff_deadline":"October 5, 2026","cvscaremark_decision_deferred_to":"January 2027"}},"quotedText":"The price of ARS's common stock declined from a closing market price of $10.54 per share on June 24, 2026 to $8.02 per share on June 25, 2026, a decline of over 23.9% in the span of just a single day.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Name partner and contact at Levi & Korsinsky, LLP"},{"name":"Ed Korsinsky, Esq.","role":"Name partner, Levi & Korsinsky, LLP"}],"products":["neffy"],"companies":[{"name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","relationship":"subject of securities class action (filer)"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm issuing solicitation"},{"name":"CVS Caremark","relationship":"pharmacy benefit manager whose neffy coverage decision is at issue in the complaint"}],"dollarAmounts":[{"amount":"$10.54","context":"ARS common stock closing price on June 24, 2026"},{"amount":"$8.02","context":"ARS common stock closing price on June 25, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Levi & Korsinsky announcing a securities class action filing and soliciting lead plaintiffs ahead of an October 5, 2026 deadline. No class certification, no settlement, and the underlying CVS Caremark coverage disclosure was already public as of June 24, 2026."},"tickerRelevance":{"others":[],"primary":"SPRY"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-class-action-solicitation","issuerAuthored":false,"retailFavoriteBoost":0,"underlyingEventNote":"formal class action filing vs. boilerplate reminder; underlying 23.9% single-day drop already public since June 24, 2026"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky, LLP announced that a securities class action was filed against ARS Pharmaceuticals on behalf of investors who purchased SPRY securities between March 9, 2026 and June 24, 2026.\n\nThe complaint alleges ARS made misleading statements about the expected timeline for expanded CVS Caremark insurance coverage for neffy; ARS disclosed on June 24, 2026 that coverage was not received by the guided July 1 deadline and that CVS Caremark deferred its decision to January 2027.\n\nOn that disclosure, SPRY shares fell from $10.54 to $8.02 in a single day, a decline of over 23.9%.\n\nThe release itself is plaintiff-firm marketing with an October 5, 2026 lead plaintiff deadline rather than new issuer disclosure; the adverse coverage news was already public in June.","key_figures":{"customDimensions":{"class_period":"March 9, 2026 to June 24, 2026","stock_decline_pct":"23.9%","close_after_disclosure":8.02,"close_before_disclosure":10.54,"lead_plaintiff_deadline":"October 5, 2026","cvscaremark_decision_deferred_to":"January 2027"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Name partner and contact at Levi & Korsinsky, LLP"},{"name":"Ed Korsinsky, Esq.","role":"Name partner, Levi & Korsinsky, LLP"}],"products":["neffy"],"companies":[{"name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","relationship":"subject of securities class action (filer)"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm issuing solicitation"},{"name":"CVS Caremark","relationship":"pharmacy benefit manager whose neffy coverage decision is at issue in the complaint"}],"dollarAmounts":[{"amount":"$10.54","context":"ARS common stock closing price on June 24, 2026"},{"amount":"$8.02","context":"ARS common stock closing price on June 25, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-03T15:53:52.445Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-class-action-solicitation","issuerAuthored":false,"retailFavoriteBoost":0,"underlyingEventNote":"formal class action filing vs. boilerplate reminder; underlying 23.9% single-day drop already public since June 24, 2026"}},"durationMs":287910,"modelName":"glm-4.7"}}